Payment overview · 2025
General Payments
$661.95
37 reported records · 8 companies
Healthcare provider profile · identity verified
Melissa Wright, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · THAYER, MO · NPI 1992762504
Verified facts
What the public records show
CMS Open Payments records show Melissa Wright, M.D. received $661.95 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 56.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BYETTA as an associated drug or biological on 60 records involving 49 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Byetta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $373.70 | 56.5% | 23 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $123.89 | 18.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.17 | 5.8% | 2 | 2025 |
| Cepheid | Unresolved — no canonical attribution shown | $33.92 | 5.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.11 | 4.8% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $29.75 | 4.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.11 | 3.5% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $7.30 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $661.95 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $266.34 | 16 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $200.23 | 14 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $102.42 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $76.72 | 5 | 2025 |
Source payment records
|
|||||
| GeneXpert Normalized: genexpert |
Device | Cepheid | $33.92 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $29.75 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BYETTA open payments reported associated product |
CMS Open Payments — General Payments 60 supporting records · 49 recipient NPIs · example record 1206154618 |
Byetta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 480 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 396 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 367 | 71 |
| Gabapentin | Gabapentin | 327 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 315 | 61 |
| Lisinopril | Lisinopril | 259 | 57 |
| Furosemide | Furosemide | 255 | 55 |
| Potassium Chloride | Potassium Chloride | 241 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 45 |
| Omeprazole | Omeprazole | 214 | 48 |
| Losartan Potassium | Losartan Potassium | 211 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 50 |
| Trazodone Hcl | Trazodone Hcl | 193 | 36 |
| Metformin Hcl | Metformin Hcl | 189 | 38 |
| Fenofibrate | Fenofibrate | 169 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 37 |
| Tramadol Hcl | Tramadol Hcl | 141 | 28 |
| Montelukast Sodium | Montelukast Sodium | 138 | 27 |
| Celecoxib | Celecoxib | 136 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 27 |
| Buspirone Hcl | Buspirone Hcl | 124 | 23 |
| Carvedilol | Carvedilol | 121 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 27 |
| Clonazepam | Clonazepam | 111 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 110 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 107 | 19 |
| Pregabalin | Pregabalin | 105 | 17 |
| Famotidine | Famotidine | 103 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 25 |
| Jardiance | Empagliflozin | 101 | 20 |
| Sertraline Hcl | Sertraline Hcl | 101 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 23 |
| Memantine Hcl | Memantine Hcl | 91 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 90 | 16 |
| Meloxicam | Meloxicam | 90 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 90 | 17 |
| Allopurinol | Allopurinol | 89 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 22 |
| Valsartan | Valsartan | 89 | 24 |
| Eliquis | Apixaban | 87 | 21 |
| Metformin Hcl Er | Metformin Hcl | 85 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 18 |
| Ibuprofen | Ibuprofen | 73 | 23 |
| Baclofen | Baclofen | 71 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 17 |
| Ozempic | Semaglutide | 68 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 20 |
| Spironolactone | Spironolactone | 66 | 13 |
| Glipizide Er | Glipizide | 64 | 11 |
| Doxepin Hcl | Doxepin Hcl | 61 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 61 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 14 |
| Azithromycin | Azithromycin | 58 | 54 |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Sucralfate | Sucralfate | 54 | 11 |
| Alprazolam | Alprazolam | 53 | suppressed |
| Trulicity | Dulaglutide | 53 | suppressed |
| Aripiprazole | Aripiprazole | 51 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | suppressed |
| Lorazepam | Lorazepam | 50 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Linzess | Linaclotide | 49 | 13 |
| Topiramate | Topiramate | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Simvastatin | Simvastatin | 47 | suppressed |
| Atenolol | Atenolol | 45 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 45 | 18 |
| Glipizide | Glipizide | 42 | suppressed |
| Primidone | Primidone | 42 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 11 |
| Fluconazole | Fluconazole | 38 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Nystatin | Nystatin | 34 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Cefdinir | Cefdinir | 30 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 22 |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Niacin Er | Niacin | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 14 |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 16 |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Quviviq | Daridorexant Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Byetta | Exenatide | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $661.95 · 37 records | ABBVIE INC. | FARXIGA, GEMTESA, GeneXpert, JOURNAVX, Ozempic, QULIPTA, SKYCLARYS, UBRELVY, VRAYLAR, VYALEV, ZURZUVAE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error